Patents by Inventor Dhruv Sareen

Dhruv Sareen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12091650
    Abstract: The invention relates to culturing brain endothelial cells, and optionally astrocytes and neurons in a fluidic device under conditions whereby the cells mimic the structure and function of the blood brain barrier. Culture of such cells in a microfluidic device, whether alone or in combination with other cells, drives maturation and/or differentiation further than existing systems.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: September 17, 2024
    Assignee: EMULATE, INC.
    Inventors: S. Jordan Kerns, Norman Wen, Carolina Lucchesi, Christopher David Hinojosa, Jacob Fraser, Geraldine Hamilton, Gad Vatine, Samuel Sances, Clive Svendsen, Daniel Levner, Dhruv Sareen
  • Publication number: 20240254449
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Application
    Filed: April 4, 2024
    Publication date: August 1, 2024
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Publication number: 20240228954
    Abstract: The invention relates to culturing brain endothelial cells, and optionally astrocytes and neurons in a fluidic device under conditions whereby the cells mimic the structure and function of the blood brain barrier. Culture of such cells in a microfluidic device, whether alone or in combination with other cells, drives maturation and/or differentiation further than existing systems.
    Type: Application
    Filed: December 5, 2023
    Publication date: July 11, 2024
    Inventors: S. Jordan Kerns, Norman Wen, Carolina Lucchesi, Christopher David Hinojosa, Jacob Fraser, Geraldine Hamilton, Gad Vatine, Samuel Sances, Clive Svendsen, Daniel Levner, Dhruv Sareen
  • Publication number: 20240158757
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors, including generation of iPSCs from lymphoblastoid B-cells and lymphoblastoid B-cell lines. Such methods and compositions find use in regenerative medicine applications.
    Type: Application
    Filed: July 14, 2023
    Publication date: May 16, 2024
    Applicant: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren Ornelas, Robert Barrett
  • Patent number: 11970714
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: April 30, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 11952592
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: April 9, 2024
    Assignee: EMULATE, INC.
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Publication number: 20240093154
    Abstract: Diabetes is a clinical condition that affects millions of people worldwide, and is treated by insulin replacement therapies. New strategies to create scalable and compatible pancreatic islets containing insulin-producing beta cells are necessary as an alternative to limited supply of cadaveric islets or multiple exogenous insulin applications. Improvements are still necessary since many immature polyhormonal cells remain, and cannot attain a monohormonal state. During human development, pancreas co-develops with endothelium and shares signals, allowing for better maturation of beta cells, and this is not included in the current differentiation protocols. The organchip microfluidic devices allows dynamic co-culture of different cells, thus resembling in vivo physiology. Here the Inventors establish organ-chip models co-culturing human iPSC-derived pancreatic precursors with iPSC-derived endothelial cells to obtain more functional and monohormonal iPSC-derived beta cells.
    Type: Application
    Filed: January 31, 2022
    Publication date: March 21, 2024
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Roberta de Souza Santos
  • Publication number: 20240084262
    Abstract: The present invention provides for methods of differentiating induced pluripotent stem cells into pancreatic progenitor cells, pancreatic ductal cells, pancreatic endocrine cells, pancreatic acinar cells, and pancreatic organoids. Cells created by these methods are also provided. Further provided are disease models and methods of drug screening.
    Type: Application
    Filed: October 29, 2021
    Publication date: March 14, 2024
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Stephen Pandol, Syairah Hanan Shaharuddin, Victoria Wang, Michael Edison P. Ramos, Aurelia Lugea, Richard T. Waldron
  • Patent number: 11913022
    Abstract: Human induced pluripotent stem cells (iPSCs) can give rise to multiple cell types and hold great promise in regenerative medicine and disease modeling applications. The Inventors herein developed a reliable two-step protocol to generate human mammary-like organoids from iPSCs. Non-neural ectoderm cell-containing spheres, referred to as mEBs, were first differentiated and enriched from iPSCs using MammoCult medium. Gene expression profile analysis suggested that mammary gland function-associated signaling pathways were hallmarks of 10-d differentiated mEBs. The Inventors generated mammary-like organoids from 10-d mEBs using 3D floating mixed gel culture and a three-stage differentiation procedure. These organoids expressed common breast tissue, luminal, and basal markers, including estrogen receptor, and could be induced to produce milk protein. These results demonstrate that human iPSCs can be directed in vitro toward mammary lineage differentiation.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: February 27, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Ying Qu, Xiaojiang Cui, Dhruv Sareen, Armando E. Giuliano
  • Publication number: 20230340420
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Application
    Filed: January 9, 2023
    Publication date: October 26, 2023
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 11767513
    Abstract: The invention relates to culturing motor neuron cells together with skeletal muscle cells in a fluidic device under conditions whereby the interaction of these cells mimic the structure and function of the neuromuscular junction (NMJ) providing a NMJ-on-chip. Good viability, formation of myo-fibers and function of skeletal muscle cells on fluidic chips allow for measurements of muscle cell contractions. Embodiments of motor neurons co-cultures with contractile myo-fibers are contemplated for use with modeling diseases affecting NMJ's, e.g. Amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: September 26, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Berhan Mandefro, Anjoscha Kaus
  • Publication number: 20230174946
    Abstract: Described herein are particular infection model systems, methods of studying infection, and method of screening compounds in various model systems. Particularly, SARS-CoV-2 is studied in these organ and infection models.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 8, 2023
    Applicants: CEDARS-SINAI MEDICAL CENTER, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Barry R. Stripp, Apoorva Mulay, Bindu Konda, Arun Sharma, Clive Svendsen, Vaithilingaraja Arumugaswami, Dhruv Sareen, Hanan Shaharuddin, Victoria Wang, Roberta S. Santos
  • Patent number: 11572545
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: February 7, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 11473061
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: October 18, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Robert Barrett, Clive Svendsen, Stephan R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani
  • Publication number: 20220282221
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Application
    Filed: February 23, 2022
    Publication date: September 8, 2022
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Patent number: 11326149
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 10, 2022
    Assignee: EMULATE, INC.
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Patent number: 11174462
    Abstract: The invention relates to culturing brain endothelial cells, and optionally astrocytes and neurons in a fluidic device under conditions whereby the cells mimic the structure and function of the blood brain barrier. Culture of such cells in a microfluidic device, whether alone or in combination with other cells, drives maturation and/or differentiation further than existing systems.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: November 16, 2021
    Assignees: EMULATE, Inc., Cedars-Sinai Medical Center
    Inventors: S. Jordan Kerns, Norman Wen, Carolina Lucchesi, Christopher David Hinojosa, Jacob Fraser, Geraldine Hamilton, Gad Vatine, Samuel Sanees, Clive Svendsen, Daniel Levner, Dhruv Sareen
  • Patent number: 11168301
    Abstract: A unified cell differentiation protocol for obtaining photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid from pluripotent stem cells is described. Also described are photoreceptor cells, retinal pigmented epithelium, and 3D retinal organoid obtained from pluripotent stem cells. Also described are a pharmaceutical composition and a medicament containing the photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid as described.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 9, 2021
    Assignee: EYESTEM RESEARCH PRIVATE LIMITED
    Inventors: Rajarshi Pal, Rajani Battu, Reena Rathod, Harshini Surendran, Kapil Bharti, Deepak Lamba, Dhruv Sareen, Mahendra Rao, Sushma Nanjunda Swamy, Vijay Bhaskar Konala Reddy, Mohanapriya Rajamoorthy
  • Publication number: 20210269776
    Abstract: Bioprinting is the layer-by-layer construction of synthetic tissues or scaffolds. Described herein is a motorized extruder which can precisely extrude and retract extrudate such as bioinks in a compact and rapidly-loadable form-factor. This includes a compact bioprinter using a stepper motor coupled with a threaded shaft to directly move the plunger of an extruder. This pneumatic-mechanical system obviates the needs for pneumatic tubing, rods, or other complex elements of existing designs. The direct drive design further allows for a lighter, smaller gantry that is capable of more precise fabrication of bioprinted constructions. This includes delicate vasculature systems that are beyond limits of existing bioprinting technologies.
    Type: Application
    Filed: June 26, 2019
    Publication date: September 2, 2021
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Andrew R. Gross, Dhruv Sareen
  • Publication number: 20210000880
    Abstract: Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic ?-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D ?-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 7, 2021
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Clive Svendsen, Dhruv Sareen